Chinese Medical E-ournals Database

Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition) ›› 2019, Vol. 15 ›› Issue (05): 571 -578. doi: 10.3877/cma.j.issn.1673-5250.2019.05.015

Special Issue:

Original Article

Ovarian seromucinous borderline tumors: a clinicopathological analysis and literature review

Jing Jia1,(), Xinlan Shi1, Yuguang Li1, Zhenqiang Li1, Lei Sun2   

  1. 1. Department of Pathology, Shijingshan Teaching Hospital of Capital Medical University, Beijing Shijingshan Hospital, Beijing 100043, China
    2. Department of Pathology, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China
  • Received:2019-07-07 Revised:2019-09-16 Published:2019-10-01
  • Corresponding author: Jing Jia
  • About author:
    Corresponding author: Jia Jing, Email:
  • Supported by:
    Project of Major Supported Specialized Subject Construction of Medical Science in Shijingshan District, Beijing(20170008); " Qingmiao" Special Funding Project of Beijing Hospitals Authority(QML20181805)
Objective

To investigate the clinicopathological characteristics, diagnosis and differential diagnosis of ovarian seromucinousborderline tumors (OSMBT), and review the related literature.

Methods

From 2005 to 2017, a total of 4 patients with OSMBT who underwent surgery at Beijing Shijingshan Hospital were selected as research subjects. The clinical data of the patients were collected by retrospective analysis method and the clinicopathological features, diagnosis of the patients were summarized. With the following keywords of " ovarian neoplasm" " seromucinous neoplasm" and " borderline neoplasm" both in Chinese and English, literature related to OSMBT were searched from Wanfang Data Knowledge Service Platform, China National Knowledge Infrastructure database and PubMed database, and literature retrieval time was set from January 1 of 2010 to January 31 of 2019. Clinicopathological features and diagnosis of OSMBT in searched literature were summarized. This study was in line with the requirement of World Medical Association of Helsinki revised in 2013.

Results

①The results of 4 patients with OSMBT in this study were as follows. General clinical data: the patients′ age were from 29 to 65 years old, with a median age of 40 years old. The major clinical manifestations included abdominal pain and masses in pelvic cavity. The stages of International Federation of Gynecology and Obstetrics (FIGO) of 4 patients all were stage Ⅰ. Surgical methods: patient 1 and 2 underwent ovarian cystectomy, and patient 3 and 4 underwent hysterectomy and bilateral salpingo-oophorectomy. Appearance observation of surgically removed specimens: the tumors of 4 patients ranged in diameter from 0.9-10.0 cm, and the average diameter of these tumors was 4.4 cm. Patient 2 was bilateral OSMBT. The masses of tumors were described as unilocular cyst with papillary architecture in patient 1 to 3, and as solid in patient 4. Histopathological results of surgically removed specimens: the OSMBT tissues showed complex branched papillary architecture, without stromal invasion. Significant neutrophil infiltration was observed in the tumor epithelium, stroma of papillary architecture and glandular lumen of tumor gland. The lining epithelium was stratified and composed mostly of endocervical-type mucous, serous epithelium and hobnail cells with eosinophilic cytoplasm, and the nuclei were mild and moderately heterogeneous, and karyokinesis was rare. Patient 2 with bilateral OSMBT was combined with endometriosis. Immunohistochemisty results of surgically removed specimens: the immunophenotype of these tumor tissues exhibited CK7+ /PAX8+ /CK20-/CDX2-. Follow-up results: none OSMBT recurrence or metastasis was found in 15 to 156 months (average of 78.8 months) follow-up of all the 4 patients. ②The results of literature review were as follows. A total of 9 literature related with OSMBT were retrieved, involving 86 cases of OSMBT patients. The main clinical manifestations of them were abdominal distension, abdominal pain, abdominal discomfort, and so on. The median age of them was 49 years old. The average diameter of these tumors was 7.9 cm. Among them, 13 cases (19.1%, 13/68) were bilateral OSMBT, 30 cases (34.9%, 30/86) were accompanied with endometriosis, and 62 cases (91.2%, 62/86) were FIGO Ⅰstage. The average follow-up time was 35.9 months among 66 patients in 8 pieces of literature and the recurrence rate of OSMBT was 6.1% (4/66).

Conclusions

OSMBT is a kind of rare ovarian neoplasm and mainly associated with endometriosis. Most OSMBT patients are young. Histopathological detection results as well as immunohistochemical marker may help in pathologic diagnosis of OSMBT. Attention should be paid to the differential diagnosis from ovarian borderline serous, mucinous tumor and carcinoma before final diagnosis. Most patients with OSMBT are FIGO Ⅰ stage and have a good prognosis. Unilateral oophorectomy and follow-up closely could be a valid proposal in young patients who wish to preserve their fertility.

表1 本组4例OSMBT患者的一般临床资料
表2 本组4例OSMBT患者手术切除标本的大体观察结果
图4 患者1(29岁)手术切除标本的活组织病理学检查,可见肿瘤上皮细胞核呈轻、中度异型性,核分裂象少见(HE染色,×200)
表3 文献复习检索的9篇文献共计报道86例OSMBT患者的临床病例资料
[1]
Kurman RJ, Carcangiu ML, Herrington S, et al. WHO classification of tumours of female reproductive organs [M]. 4th ed. Lyon: IARC, 2014: 38-40.
[2]
宋光耀,王亚萍,李广慧,等. 卵巢交界性浆黏液性肿瘤的临床病理学特征[J]. 中国医师进修杂志,2019, 42(1): 10-13.
[3]
董燕燕,刘云霄,屈重霄. 卵巢交界性浆黏液性肿瘤临床病理特征分析[J]. 肿瘤研究与临床,2018, 30(9): 603-606.
[4]
孙力,宋艳,李宁,等. 黏液性卵巢交界性肿瘤的临床病理特征及复发危险因素[J]. 中华肿瘤杂志,2017, 39(8): 589-594.
[5]
陈友权,魏清,张玉荣,等. 卵巢交界性肿瘤12例临床病理分析[J]. 中国现代医生,2018, 56(23): 133-136.
[6]
Newton CL, Brockbank E, Singh N, et al. A case of stage 4B seromucinous ovarian borderline tumor with endometriosis and review of the literature[J]. Int J Gynecol Pathol, 2017, 36(2): 195-199.
[7]
Kurata Y, Kido A, Moribata Y, et al. Differentiation of seromucinous borderline tumor from serous borderline tumor on MR imaging[J]. Magn Reson Med Sci, 2018, 17(3): 211-217.
[8]
Nakamura E, Sato Y, Moriguchi S, et al. Ovarian seromucinous borderline tumor and clear cell carcinoma: an unusual combination[J]. Case Rep Obstet Gynecol, 2015, 2015: 690891.
[9]
Karpathiou G, Chauleur C, Corsini T, et al. Seromucinous ovarian tumor A comparison with the rest of ovarian epithelial tumors[J]. Ann Diagn Pathol, 2017, 27: 28-33.
[10]
D′Angelo E, Dadmanesh F, Pecorelli S, et al. Squamous cell carcinoma of the ovary arising from a mucinous cystic tumor of endocervical (müllerian) type[J]. Int J Gynecol Pathol, 2010, 29(6): 529-532.
[11]
Fox H, Langley FA. Tumors of the Ovary[M]. Chicago: William Heinemann, 1976: 252.
[12]
Rutgers JL, Scully RE. Ovarian Mullerian mucinous papillary cystadenomas of borderline malignancy. A clinicopathologic analysis[J]. Cancer, 1988, 61(2): 340-348.
[13]
Rutgers JL, Scully RE. Ovarian mixed-epithelial papillary cystadenomas of borderline malignancy. A clinicopathologic analysis[J]. Cancer, 1988, 61(3): 546-554.
[14]
Shappell HW, Riopel MA, Smith Sehdev AE, et al. Diagnostic criteria and behavior of ovarian seromucinous (endocervical-type mucinous and mixed cell-type) tumors: atypical proliferative (borderline) tumors, intraepithelial, microinvasive, and invasive carcinomas[J]. Am J Surg Pathol, 2002, 26(12): 1529-1541.
[15]
Tavassoli FA, Devilee P. 乳腺及女性生殖器官肿瘤病理学和遗传学[M].程虹,译. 北京:人民卫生出版社,2006: 171-176.
[16]
Kurman RJ, Shih IM. Seromucinous tumors of the ovary. What′s in a name?[J]. Int J Gynecol Pathol, 2016, 35(1): 78-81.
[17]
郑文新,沈丹华,郭东辉. 妇产科病理学[M]. 北京:科学出版社,2013: 587-588.
[18]
倪皓,周晓军. 免疫组化在卵巢交界性肿瘤诊断和鉴别诊断中的研究进展[J].诊断病理学杂志,2016, 23(6): 462-465.
[19]
Chene G, Ouellet V, Rahimi K, et al. The ARID1A pathway in ovarian clear cell and endometrioid carcinoma, contiguous endometriosis, and benign endometriosis[J]. Int J Gynaecol Obstet, 2015, 130(1): 27-30.
[20]
Kim KR, Choi J, Hwang JE, et al. Endocervical-like (Müllerian) mucinous borderline tumors of the ovary are frequently associated with the KRAS mutation[J]. Histopathology, 2010, 57(4): 587-596.
[21]
Matias-Guiu X, Stewart CJR. Endometriosis-associated ovarian neoplasia[J]. Pathology, 2018, 50(2): 190-204.
[22]
Taylor J, McCluggage WG. Ovarian seromucinous carcinoma: report of a series of a newly categorized and uncommon neoplasm[J]. Am JSurgPathol, 2015, 39(7): 983-992.
[23]
唐绍娴,孙艺华,许燕. 卵巢浆黏液性癌临床病理学分析[J].中华病理学杂志,2016, 45(11): 774-779.
[1] Minrong Ma, Cong Li, Qin Zhou. Current research status of treatment of cervical cancer[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2023, 19(05): 497-504.
[2] Changsheng Lin, Jun Zhan, Xue Xiao. Genetic testing and precision molecular targeted therapy in diagnosis and treatment of epithelial ovarian caner[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2023, 19(05): 505-510.
[3] Dan Luo, Weimin Kong, Shuning Chen, Xiaoling Zhao, Yunkai Xie. Differences in epithelial mesenchymal transition-related biological markers between in-situ and ectopic endometrial epithelial cells in endometriosis patients[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2023, 19(05): 530-539.
[4] Juan Gu, Qingqing Sun, Fangfang Hu, Yijuan Cao, Yujuan Qi. Clinical application of endometrial receptivity array to improve pregnancy outcomes in women with repeated embryo implantation failure[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2023, 19(05): 582-587.
[5] Wenrong Dai, Lijuan Zhao, Zhihui Li. Research progress of influence of extracellular vesicles on embryo implantation[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2023, 19(05): 616-620.
[6] Dongjie Zhou, Min Jiang, Hairui Fan, Lingling Gao, Xiang Kong, Dan Lu, Liping Wang. Current research progress on non-coding RNA in follicular development and maturation[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2023, 19(04): 387-393.
[7] Huizhu Chen, Yingkun Guo, Xinrong Wang, Gang Ning, Xijian Chen. Current research status on the " dualistic model" of epithelial ovarian cancer and its molecular biology[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2023, 19(04): 394-402.
[8] Chunying Han, Tingting Wang, Yanyan Li, Jinxia Piao. Current research status on predictors of lymphatic vascular invasion in patients with endometrial carcinoma[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2023, 19(04): 403-409.
[9] Xingchen Liu, Juan Liu, Baobao Wei, Jie Liu, Hui Liu. Correlation analysis of abnormal expression of XIAP and XAF1 with ovarian cancer[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2023, 19(04): 419-427.
[10] Zhaomin Zeng, Haiyan Yu. Clinical cognition of superfemale syndrome[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2023, 19(02): 145-150.
[11] Quan Wei, Shen Zhang, Huijia Chen, Heng Zou, Lina Hu. Current research progress on correlation between female reproductive tract microbiota and assisted reproductive technology[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2023, 19(02): 151-155.
[12] Yanyan Liu, Xi Tan, Xue Peng. Pregnancy complicated with papillary urothelial neoplasms of low malignant potential: a case report and literature review[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2023, 19(02): 212-218.
[13] Ming Zhang, Ji Wang, Wenxing Zhao. Clinical application of limited pancreatic resection with pancreatic function preservation in benign and borderline tumors[J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(05): 562-565.
[14] Dingran Wang, Hongbin Chi. Effects of autoimmune thyroiditis on embryo transfer outcomes in patients with endometriosis[J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(06): 682-688.
[15] Yuxin Liu, Zihan Wang, Yixin Zhang, Yongjie Luan, Kai Meng. Research progress of Wilms' tumor gene 1 in the pathogenesis of ovarian diseases[J]. Chinese Journal of Diagnostics(Electronic Edition), 2023, 11(03): 178-183.
Viewed
Full text


Abstract